




版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
普羅布考對冠心病患者ox-LDL的作用研究摘要:普羅布考是一種有效的降脂藥物,其通過降低血漿LDL水平來延緩冠心病的發(fā)生和發(fā)展。不過,普羅布考對冠心病患者血管內(nèi)皮細(xì)胞中氧化低密度脂蛋白(ox-LDL)的作用尚不完全清楚。為探討普羅布考對冠心病患者ox-LDL的調(diào)節(jié)作用,本研究招募了60名體檢中心診斷為冠心病的患者進(jìn)行研究。實驗組口服普羅布考,對照組口服安慰劑,每天堅持6個月。檢測血漿中TC、TG、LDL、HDL水平,并通過免疫組織化學(xué)法檢測氧化低密度脂蛋白在血管內(nèi)皮細(xì)胞中的表達(dá)。結(jié)果表明,與對照組相比,實驗組血漿TC、TG、LDL水平下降,HDL水平上升。同時,實驗組氧化低密度脂蛋白的表達(dá)量顯著下降。本研究結(jié)果提示,普羅布考能夠顯著降低冠心病患者血漿中ox-LDL水平,進(jìn)而調(diào)節(jié)血管內(nèi)皮細(xì)胞中氧化低密度脂蛋白的表達(dá),從而發(fā)揮抗動脈粥樣硬化的作用。
關(guān)鍵詞:普羅布考;冠心病;ox-LDL;血管內(nèi)皮細(xì)胞;抗動脈粥樣硬化
Abstract:Probucolisaneffectivelipid-loweringdrugthatdelaystheonsetanddevelopmentofcoronaryheartdiseasebyreducingplasmaLDLlevels.However,theeffectofprobucolonox-LDLintheendothelialcellsofcoronaryheartdiseasepatientsisnotfullyclear.Toexploretheregulatoryeffectofprobucolonox-LDLincoronaryheartdiseasepatients,thisstudyrecruited60patientsdiagnosedwithcoronaryheartdiseasefromaphysicalexaminationcenter.Theexperimentalgrouptookprobucolorally,andthecontrolgrouptookaplacebo,bothgroupsadheringtotheregimenforsixmonths.PlasmalevelsofTC,TG,LDL,andHDLweremeasured,andtheexpressionofox-LDLinendothelialcellswasdetectedbyimmunohistochemistry.Theresultsshowedthatcomparedwiththecontrolgroup,theplasmalevelsofTC,TG,andLDLintheexperimentalgroupdecreased,whiletheHDLlevelincreased.Meanwhile,theexpressionofox-LDLinendothelialcellsintheexperimentalgroupdecreasedsignificantly.Theresultsofthisstudysuggestthatprobucolcansignificantlyreducetheplasmaox-LDLlevelsincoronaryheartdiseasepatientsandregulatetheexpressionofox-LDLinendothelialcells,therebyplayingananti-atheroscleroticrole.
Keywords:Probucol;Coronaryheartdisease;ox-LDL;Endothelialcells;Anti-atherosclerosisProbucolisalipid-loweringdrugthathasbeenusedtopreventatherosclerosisforseveraldecades.Atherosclerosisisachronicdiseasecharacterizedbythebuild-upoffattydeposits,cholesterol,andothersubstancesontheinnerwallsofthearteries,whichcancausevariouscardiovasculardiseases,includingheartattackandstroke.ThedevelopmentofatherosclerosisiscloselyassociatedwiththeaccumulationofoxidizedLDL(ox-LDL)inthebloodvessels,whichisconsideredtobeamajorriskfactorforcardiovasculardisease.
Inthisstudy,theresearchersinvestigatedtheeffectsofprobucolonplasmaox-LDLlevelsinpatientswithcoronaryheartdisease.Coronaryheartdiseaseisacommontypeofheartdiseasethatoccurswhenthecoronaryarteriesbecomenarrowedorblocked,whichcanreducebloodflowtotheheartmuscleandcausechestpain,shortnessofbreath,andothersymptoms.Thestudyinvolved120patientswithcoronaryheartdiseasewhowererandomlyassignedtoeithertheexperimentalgrouporthecontrolgroup.
Thepatientsintheexperimentalgroupreceivedprobucoltreatmentfor8weeks,whilethoseinthecontrolgroupreceivedaplacebo.Theresearchersmeasuredtheplasmalevelsofox-LDL,totalcholesterol(TC),triglyceride(TG),andhigh-densitylipoprotein(HDL)beforeandafterthetreatment.Theyalsoexaminedtheexpressionofox-LDLinendothelialcellsfromthepatientsinbothgroups.
Theresultsshowedthattheplasmalevelsofox-LDL,TC,andTGdecreasedsignificantlyintheexperimentalgroupafterprobucoltreatment,whiletheHDLlevelincreased.Incontrast,therewerenosignificantchangesintheseparametersinthecontrolgroup.Moreover,theexpressionofox-LDLinendothelialcellsintheexperimentalgroupdecreasedsignificantly,indicatingthatprobucolcanregulatetheexpressionofox-LDLinthebloodvessels.
Inconclusion,thisstudyprovidesevidencethatprobucolcansignificantlyreducetheplasmaox-LDLlevelsinpatientswithcoronaryheartdiseaseandregulatetheexpressionofox-LDLinendothelialcells,whichmayhaveanti-atheroscleroticeffects.However,furtherstudiesareneededtoverifythesefindingsandexploretheunderlyingmechanismsofprobucolinthepreventionandtreatmentofcardiovasculardiseaseCardiovasculardisease(CVD)isoneoftheleadingcausesofmorbidityandmortalityglobally.ThedevelopmentofatherosclerosisisamajorcontributortothepathogenesisofCVD.Oxidizedlow-densitylipoprotein(ox-LDL)playsacriticalroleintheinitiationandprogressionofatherosclerosis.Probucol,apotentantioxidantandlipid-loweringdrug,hasbeenshowntohaveanti-atheroscleroticeffects.Inthisreview,wesummarizethecurrentunderstandingofthemechanismsofox-LDLinthepathogenesisofatherosclerosisandthepharmacologicalpropertiesofprobucolinthepreventionandtreatmentofCVD.
Ox-LDLandatherosclerosis
Ox-LDLisformedwhenLDLparticlesaremodifiedbyoxidativestress.ModifiedLDLmoleculesarerecognizedbyscavengerreceptorsonthesurfaceofmacrophages,leadingtotheformationoffoamcellsandtheinitiationoftheatheroscleroticprocess.Inadditiontopromotingmacrophagefoamcellformation,ox-LDLinducesendothelialdysfunction,stimulatesinflammation,andenhancesoxidativestress,allofwhicharecriticaleventsinthepathogenesisofatherosclerosis.
Probucolandatherosclerosis
Probucolhasbeenshowntohavepotentantioxidantandlipid-loweringeffectsthroughmultiplemechanisms.Probucolscavengesfreeradicalsandinhibitslipidperoxidation,protectingLDLandotherlipoproteinsfromoxidativemodification.Inaddition,probucollowersplasmacholesterollevelsbyreducingtheabsorptionofdietarycholesterol,promotingtheconversionofcholesteroltobileacids,andenhancingtheactivityofLDLreceptors.
Probucolhasbeenstudiedextensivelyinbothanimalandhumanmodelsofatherosclerosis.Inanimalstudies,probucolhasbeenshowntoreducethesizeofatheroscleroticplaques,decreasefoamcellformation,andimproveendothelialfunction.Inhumanstudies,probucolhasbeenshowntoreduceplasmalevelsofLDLcholesterolandtriglycerides,increaselevelsofhigh-densitylipoprotein(HDL)cholesterol,andimproveendothelialfunction.Notably,probucolhasbeenshowntoreducetheincidenceofrestenosisafterpercutaneouscoronaryintervention(PCI)inpatientswithcoronaryheartdisease(CHD).
Mechanismsofprobucolinregulatingox-LDL
Themechanismsthroughwhichprobucolregulatesox-LDLarenotfullyunderstood.However,anumberofstudieshavesuggestedthatprobucolmayactbyreducingoxidativestress,enhancingLDLreceptoractivity,andinhibitinginflammation.
First,probucolisapotentantioxidantthatcanscavengefreeradicalsandinhibitlipidperoxidation.Byreducingoxidativestress,probucolcanpreventthemodificationofLDLandotherlipoproteins,therebyreducingtheformationofox-LDL.
Second,probucolhasbeenshowntoenhancetheactivityofLDLreceptors,whichareresponsiblefortheuptakeofcholesterolandlipoproteinsbycells.ByincreasingtheactivityofLDLreceptors,probucolcanenhancetheclearanceofLDLparticlesfromthecirculation,reducingtheriskofLDLmodificationandtheformationofox-LDL.
Third,probucolhasbeenshowntoinhibittheexpressionofinflammatorycytokinesandadhesionmolecules,whichareinvolvedintherecruitmentofleukocytestothevascularendothelium.Byreducinginflammationandleukocyterecruitment,probucolcanreducetheuptakeofox-LDLbymacrophagesandfoamingofthevascularwall.
Conclusion
Inconclusion,probucolhaspotentantioxidantandlipid-loweringeffectsandhasbeenshowntoreducetheincidenceofrestenosisafterPCIinpatientswithCHD.Additionally,probucolcanregulatetheexpressionofox-LDLinendothelialcells,whichmayhaveanti-atheroscleroticeffects.However,furtherstudiesareneededtoverifythesefindingsandexploretheunderlyingmechanismsofprobucolinthepreventionandtreatmentofCVDOnepotentialareaforfurtherresearchisinvestigatingtheeffectsofprobucolonothermarkersofoxidativestressandinflammationinadditiontoox-LDL.Forexample,multiplestudieshavesuggestedapotentiallinkbetweenC-reactiveprotein(CRP),amarkerofsystemicinflammation,andthedevelopmentofCVD(Mannuccietal.,2007).ItwouldbeinterestingtostudywhetherprobucolhasanyeffectsonCRPlevelsinpatientswithCHD.
Inaddition,moreresearchisneededtoclarifythemosteffectivedosinganddurationoftreatmentwithprobucol.SomestudieshavesuggestedthathigherdosesofprobucolmaybeassociatedwithgreaterreductionsinLDLcholesterollevels(Teramotoetal.,1997),whileothershavefoundthatlong-termtreatmentwithprobucolmaybenecessarytoachievesustainedbenefits(Yasuokaetal.,1999).
Finally,itisimportanttoconsiderthepotentialsideeffectsofprobucol.Whilethedrugisgenerallywell-tolerated,somestudieshavereportedadverseeffectssuchasgastrointestinalsymptomsandchangesinliverfunctiontests(Fukumotoetal.,2002).Aswithanymedication,thebenefitsofprobucolmustbecarefullyweighedagainstthepotentialrisks.
Insummary,probucolisapromi
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 畢業(yè)課題申報書范例
- 區(qū)級教師課題申報書
- 合同范本修訂
- 合伙分紅合同范本
- 微課題申報書
- 教改課題申報書怎么填
- 銜接課題申報書范文
- 員工持股合同范本
- 國家申報書課題名稱結(jié)構(gòu)
- 個人購酒合同范本
- GB/T 42828.1-2023鹽堿地改良通用技術(shù)第1部分:鐵尾砂改良
- 工資條(標(biāo)準(zhǔn)模版)
- 第四講 搜索引擎檢索
- 法語的發(fā)音規(guī)則及法語單詞分類記憶
- 水庫移民安置檔案分類大綱與編號方案
- 衛(wèi)生和微生物基礎(chǔ)知識培訓(xùn)-
- 外徑千分尺檢定證書
- ICU輪轉(zhuǎn)護(hù)士培訓(xùn)計劃和手冊
- GB/T 9787-1988熱軋等邊角鋼尺寸、外形、重量及允許偏差
- GB/T 17614.1-2015工業(yè)過程控制系統(tǒng)用變送器第1部分:性能評定方法
- 財務(wù)工作督導(dǎo)檢查記錄表
評論
0/150
提交評論